Nanomix Corp. has announced confirmation of registration from the Medicines & Healthcare products Regulatory Agency of the United Kingdom for the Nanomix eLab system and the S1 Panel Cartridge.
Nanomix is a leader in the development of mobile, affordable, point-of-care diagnostic, and this registration is considered a step forward for faster, more affordable diagnosis. With the help of the Nanomix eLab analyzer with S1 Panel Cartridge, healthcare providers are better able to diagnose and treat patients with sepsis and other critical infections as a result of multiple host-response biomarker results.
“This registration is an important step in accelerating the introduction and availability of Nanomix products to markets and patients throughout the United Kingdom,” John Hardesky, chief commercial officer of Nanomix, said in a release. “The S1 Panel provides multiple test results from a single patient sample and a single cartridge in less than 11 minutes. Timely diagnostics, by the bedside, are targeted to improve treatment and transition of care decisions in both point-of-care and hospital settings.”
The Nanomix eLab is a mobile, hand-held immunoassay and chemistry diagnostic system. The Nanomix eLab can get patients on track to treatment faster with results available in minutes. Other benefits are an affordable cost and portability, as well as accurate, quantitative results comparable in quality to those provided by central lab testing.
The Nanomix eLab S1 Panel Cartridge, the release said, is wholly contained, disposable cartridge technology. It contains reagents and biosensors that provide quantitative measurement of two biomarkers, C-reactive protein (CRP) and procalcitonin (PCT) and the metabolite lactate (LAC), each of which is instrumental in assessing critical infections.
The product, according to the release, provides sample-to-answer results that healthcare providers can use to make decisions on antibiotic therapy for patients with suspected or confirmed sepsis or lower respiratory tract infections (LRTI). Among these infections may be community-acquired pneumonia (CAP), acute bronchitis and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in an inpatient setting or Emergency Department.